Open-Source Artificial Pancreas System Shows Promise for Type 1 Diabetes in Brazil

The Android Artificial Pancreas System (AAPS) is an open-source software platform that works with existing diabetes devices to automate insulin delivery. Unlike commercial closed-loop systems sold by major manufacturers, AAPS is developed by a community of volunteers and can be adapted to work with standard continuous glucose monitors and insulin pumps. This makes it significantly cheaper and potentially available to people in regions where branded systems are too expensive or unavailable.

Researchers in Brazil surveyed 371 people with Type 1 diabetes: 62 who were using AAPS and 309 who were not. The AAPS setup included a continuous glucose monitor to track blood sugar, a wireless transmitter called MiaoMiao, and a standard insulin pump controlled by the AAPS software. The team measured blood sugar control, the frequency of severe low blood sugar events, and participants' quality of life.

People using AAPS spent an average of 78.5% of their time with blood sugar in their target range—a strong result that reflects good day-to-day control. Their average HbA1c, a measure of long-term blood sugar control, dropped from 7.3% to 6.5%, a statistically significant improvement.

Compared to the group not using automated insulin delivery, AAPS users experienced fewer severe low blood sugar events and reported better quality of life. However, the study also identified room for improvement: about 1 in 4 AAPS users still had time in range below 70%, and some users spent more time in level-2 hypoglycemia (very low blood sugar) than is ideal.

This study adds to growing evidence that open-source, community-developed artificial pancreas systems can safely and effectively improve blood sugar control for people with Type 1 diabetes. Because AAPS is affordable and flexible, it may help people in lower-income countries and underserved areas access automated insulin delivery—technology that has traditionally been available only to those who can afford expensive commercial systems.

The results show AAPS is not perfect; some users still struggled to achieve optimal time in range or experienced too much low blood sugar. Like any diabetes tool, AAPS works best when combined with ongoing diabetes education, professional support, and regular adjustments. If you're interested in learning whether an automated insulin system might help you, talk with your diabetes care team about your individual goals and options.

Source: Archives of endocrinology and metabolism. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.